checkAd

     111  0 Kommentare Spectral Medical Announces that its Wholly-Owned Subsidiary Dialco Medical has been Granted FDA IDE Authorization to Conduct a Trial of DIMI for Home Hemodialysis Use - Seite 3

    The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement.

    Contact:    
    Dr. Paul Walker Mr. Chris Seto Ali Mahdavi
    President and CEO COO & CFO Capital Markets & Investor
    Spectral Medical Inc. Spectral Medical Inc. Relations
    416-626-3233 ext. 2100  416-626-3233 ext. 2004  416-962-3300
    pwalker@spectraldx.com  cseto@spectraldx.com  am@spinnakercmi.com
         
    David Waldman/Natalya Rudman    
    US Investor Relations    
    Crescendo Communications, LLC    
    212-671-1020    
    edt@crescendo-ir.com    

     
    Seite 3 von 3



    globenewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors


    Verfasst von globenewswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    Spectral Medical Announces that its Wholly-Owned Subsidiary Dialco Medical has been Granted FDA IDE Authorization to Conduct a Trial of DIMI for Home Hemodialysis Use - Seite 3 TORONTO, Feb. 23, 2021 (GLOBE NEWSWIRE) - Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), today announced that its wholly-owned subsidiary, Dialco Medical Inc. (“Dialco”), has been granted Investigational Device Exemption (IDE) …